Senior Analyst Financial Reporting
Apply NowCompany: Avadel Management Corporation
Location: Chesterfield, MO 63017
Description:
About Avadel Pharmaceuticals plc
Who We Are: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Oxybate therapy is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients living with narcolepsy. However, other approved oxybate products are immediate release formulations requiring two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night. LUMRYZ TM (sodium oxybate) extended release for oral suspension, applies our proprietary drug delivery technology to allow for a single bedtime dose, eliminating the need to have a forced awakening during the middle of the night and giving patients the chance for an uninterrupted night's sleep. An extended-release medication sounds like a simple innovation, but it has been lacking for more than 20 years, and we believe this can be transformative for people with narcolepsy. For more information, please visit www.avadel.com or check out narcolespydisrupts.com.
What We Do: LUMRYZ was approved by the U.S. Food and Drug Administration (FDA) on May 1, 2023, to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The FDA also found LUMRYZ to be clinically superior to currently marketed twice-nightly oxybate products and granted LUMRYZ seven years of Orphan Drug Exclusivity. In particular, FDA found that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products by providing a once-nightly dosing regimen that avoids nocturnal awakening to take a second dose.
How We Work: At Avadel, patients are the reason we exist, and our employees are our greatest competitive advantage - our "secret sauce." The way we work is as important as the results we achieve. Our employees work together as ONE team and live our Values, which is what makes working at Avadel so special and why we will win for patients. Our ONE Team approach fosters a culture based on being relentless for patients, having confidence with humility, being courageous, taking insights to impact, and togetherness. In everything we do, we live the Avadel Values so we can be our best for our patients, our community and each other.
We need individuals who will dive in, roll up their sleeves, and join us to continue the LUMRYZ launch and our mission to serve the narcolepsy community.
Position Summary:
The Senior Analyst, Financial Reporting will be a critical member of the finance team and is responsible for the preparation of the Company's SEC filings, technical accounting research and analysis, and for the internal preparation of ad hoc reports and analyses. This individual will assist the finance team as Avadel prepares for the Corporate Sustainability Reporting Directive ("CSRD") and the Securities and Exchange Commission ("SEC") climate-related disclosure reporting requirements. The Senior Analyst, Financial Reporting will work closely with the Director of External Reporting and cross-functional business partners, offering opportunities for growth and development. Avadel offers a dynamic and fast-paced work environment, so the ability to learn and adapt quickly is essential.
Essential Functions:
External Reporting Activities:
Internal Reporting Activities:
Experience and Qualifications:
Competencies and Behaviors:
Avadel is committed to facilitating an open, honest, inclusive, transparent, and productive work environment where we work together as ONE team and ONE culture to be our best for patients, customers, and each other. Avadel is committed to equal employment opportunities and non-discrimination in employment. We believe that all employees and applicants should be treated with courtesy, dignity, and respect. Avadel does not discriminate in employment on the basis of race, color, religion, sex, sexual orientation, national origin, age, disability, genetic information, marital status, ancestry, gender, gender identity, pregnancy, status as a covered veteran, or any other characteristic protected by federal, state, and/or local law. It is our intent to comply with federal, state, and local laws, regulations, and guidelines in our employment practices and in our service to our clients. This policy applies to all terms and conditions of employment including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.
Who We Are: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Oxybate therapy is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients living with narcolepsy. However, other approved oxybate products are immediate release formulations requiring two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night. LUMRYZ TM (sodium oxybate) extended release for oral suspension, applies our proprietary drug delivery technology to allow for a single bedtime dose, eliminating the need to have a forced awakening during the middle of the night and giving patients the chance for an uninterrupted night's sleep. An extended-release medication sounds like a simple innovation, but it has been lacking for more than 20 years, and we believe this can be transformative for people with narcolepsy. For more information, please visit www.avadel.com or check out narcolespydisrupts.com.
What We Do: LUMRYZ was approved by the U.S. Food and Drug Administration (FDA) on May 1, 2023, to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The FDA also found LUMRYZ to be clinically superior to currently marketed twice-nightly oxybate products and granted LUMRYZ seven years of Orphan Drug Exclusivity. In particular, FDA found that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products by providing a once-nightly dosing regimen that avoids nocturnal awakening to take a second dose.
How We Work: At Avadel, patients are the reason we exist, and our employees are our greatest competitive advantage - our "secret sauce." The way we work is as important as the results we achieve. Our employees work together as ONE team and live our Values, which is what makes working at Avadel so special and why we will win for patients. Our ONE Team approach fosters a culture based on being relentless for patients, having confidence with humility, being courageous, taking insights to impact, and togetherness. In everything we do, we live the Avadel Values so we can be our best for our patients, our community and each other.
We need individuals who will dive in, roll up their sleeves, and join us to continue the LUMRYZ launch and our mission to serve the narcolepsy community.
Position Summary:
The Senior Analyst, Financial Reporting will be a critical member of the finance team and is responsible for the preparation of the Company's SEC filings, technical accounting research and analysis, and for the internal preparation of ad hoc reports and analyses. This individual will assist the finance team as Avadel prepares for the Corporate Sustainability Reporting Directive ("CSRD") and the Securities and Exchange Commission ("SEC") climate-related disclosure reporting requirements. The Senior Analyst, Financial Reporting will work closely with the Director of External Reporting and cross-functional business partners, offering opportunities for growth and development. Avadel offers a dynamic and fast-paced work environment, so the ability to learn and adapt quickly is essential.
Essential Functions:
External Reporting Activities:
- Prepare annual reports on Form 10-K, quarterly reports on Form 10-Q and annual reports for the statutory accounts.
- Compile documentation and support for the quarterly and annual filings.
- Assist in researching and documenting accounting disclosure requirements.
- Review XBRL documents for accuracy, consistency, and completeness of data tagging.
- Assist in the annual external audit and quarterly review process.
- Assist with the implementation of CSRD reporting and SEC climate-related disclosures for the Company.
- Prepare other ad-hoc analysis and special projects, as requested.
Internal Reporting Activities:
- Assist with the preparation of the internal monthly reporting package.
- Prepare the monthly stock-based compensation entries and weighted average share calculations.
- Provide technical accounting assistance by researching and drafting technical accounting memos as required.
- Identify areas of process improvement and assist in implementing changes.
- Implement and maintain reporting procedures to comply with internal control requirements.
- Support month end, quarter end, and year end closing as required.
- Participate in other projects as required.
Experience and Qualifications:
- Bachelor's Degree in Accounting or equivalent required
- CPA certification required
- 3+ years of experience in public accounting and/or industry accounting sector
- Advanced knowledge of financial statements and technical accounting under US GAAP
- Pharmaceutical or life sciences industry experience a plus
- Proficient in Excel and Microsoft Office Suite
- Oracle HFM/FCCS experience a plus
- Workiva W-Desk experience a plus
Competencies and Behaviors:
- Ability to fully own projects from execution through to completion and documentation.
- Excellent attention to detail and accuracy.
- Excellent verbal and written communication skills.
- Strong time-management and prioritization skills, with an emphasis on attention to detail.
- Ability to work independently while understanding the necessity for communicating and coordinating work efforts with other employees and departments.
- Ability to handle confidential information.
- Flexibility in a Hybrid work environment.
Avadel is committed to facilitating an open, honest, inclusive, transparent, and productive work environment where we work together as ONE team and ONE culture to be our best for patients, customers, and each other. Avadel is committed to equal employment opportunities and non-discrimination in employment. We believe that all employees and applicants should be treated with courtesy, dignity, and respect. Avadel does not discriminate in employment on the basis of race, color, religion, sex, sexual orientation, national origin, age, disability, genetic information, marital status, ancestry, gender, gender identity, pregnancy, status as a covered veteran, or any other characteristic protected by federal, state, and/or local law. It is our intent to comply with federal, state, and local laws, regulations, and guidelines in our employment practices and in our service to our clients. This policy applies to all terms and conditions of employment including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.